Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy
David B. Agus
, Christopher J. Sweeney
, Michael J. Morris
, David S. Mendelson
, Douglas G. McNeel
, Frederick R. Ahmann
, Jin Wang
, Mika K. Derynck
, Kimmie Ng
, Benjamin Lyons
, David E. Allison
, Michael W. Kattan
, Howard I. Scher
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy'. Together they form a unique fingerprint.